Multicenter, Double-blind Comparison of Sertraline and Placebo in the Treatment of Posttraumatic Stress Disorder

Davidson, Jonathan; Rothbaum, Barbara O.; Kolk, Bessel A. van der; Sikes, Carolyn; Farfel, Gail

doi:10.1001/archpsyc.58.5.485

Cited by 415 publications

(223 citation statements)

References 43 publications

Supporting

Mentioning

208

Contrasting

Unclassified

Order By: Relevance

“…Recommendations in the Society for Traumatic Stress Studies guidelines (Benedek et al, 2009;Foa, Keane, and Friedman, 1999) and the American Psychiatric Association guidelines (American Psychiatric Association, 2004) also support the measure. Randomized controlled trials and meta-analyses of the results of those trials support the use of an SSRI/SNRI as a first-line agent for the treatment of PTSD (Brady et al, 2000;Davidson, Rothbaum, et al, 2001;Foa, Davidson, and Frances, 1999;Jonas et al, 2013;Stein, Ipser, and Seedat, 2009), as does a recent IOM report (Institute of Medicine, 2012). (For more detail, see Appendix A.…”

Section: Quality Measure Results For Ptsd Measure Overviewmentioning

confidence: 83%

“…Empirical support, from randomized control trials and meta analyses of those trials, exists to justify the use of SSRIs and SNRIs as a first-line agent for the treatment of PTSD (Brady et al, 2000;Davidson, Rothbaum, et al, 2001;Foa, Davidson, and Frances, 1999;Jonas et al, 2013;Stein, Ipser, and Seedat, 2009). A recent review of PTSD pharmacotherapy indicated that the largest and greatest number of trials showing efficacy have been with the SSRIs (Ipser and Stein, 2012).…”

Section: Research Evidencementioning

confidence: 99%

See 1 more Smart Citation

Quality of Care for PTSD and Depression in the Military Health System: Phase I Report

Hepner¹,

Sloss²,

Roth³

et al. 2016

View full text Add to dashboard Cite

This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions.html.The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest.RAND's publications do not necessarily reflect the opinions of its research clients and sponsors. For more information on this publication, visit www.rand.org/t/RR978 Support RANDPublished by the RAND Corporation, Santa Monica, Calif. © Copyright 2016 RAND CorporationR® is a registered trademark. Cover: U.S. Air Force photo by Senior Airman Tabatha Zarrella iii PrefaceThe U.S. Department of Defense (DoD) strives to maintain a physically and psychologically healthy, mission-ready force, and the care provided by the Military Health System (MHS) is critical to meeting this goal. Given the rates of posttraumatic stress disorder (PTSD) and depression among U.S. service members, attention has been directed to ensuring the quality and availability of programs and services targeting these and other psychological health (PH) conditions. Understanding the current quality of care for PTSD and depression is an important step toward future efforts to improve care across the MHS.To help determine whether the service members with PTSD and/or depression are receiving evidence-based care and whether there are disparities in care quality by branch of service, geographic region, and service member characteristics (e.g., gender, age, pay grade, race/ethnicity, deployment history), DoD's Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury (DCoE) asked the RAND Corporation to conduct a review of the administrative data and medical records of service members diagnosed with PTSD and/or depression and to recommend areas on which the MHS could focus its efforts to continuously improve the quality of care provided to all service members.This report should be of interest to MHS personnel who provide care for service members with PTSD and/or depression. It should also be useful to those responsible for monitoring the quality of that care and developing evidence-based quality measures to improve care for service members and individuals with PTSD or depression in other health systems.This research was sponsored by DCoE and conducted within the Forces and Resources Policy Center of the RAND National Defense Research Institute, a federally funded research and development center sponsored by the Office of ...

show abstract

Section: Quality Measure Results For Ptsd Measure Overviewmentioning

confidence: 83%

Section: Research Evidencementioning

confidence: 99%

Quality of Care for PTSD and Depression in the Military Health System: Phase I Report

Hepner¹,

Sloss²,

Roth³

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The SSRIs are the most commonly prescribed medication for the treatment of PTSD. Large RCTs conducted with sertraline (Brady et al [78], Davidson et al [79]) and paroxetine (Marshall et al [80]) resulted in U.S. Food and Drug Administration approval for their use with PTSD. The effect size for overall symptom relief is modest, d = 0.3-0.4.…”

Section: Antidepressant Agentsmentioning

confidence: 99%

Treatment of sleep disturbances in posttraumatic stress disorder: A review

Schoenfeld

DeViva²,

Manber³

2012

JRRD

219

View full text Add to dashboard Cite

Abstract-Sleep disturbances are among the most commonly reported posttraumatic stress disorder (PTSD) symptoms. It is essential to conduct a careful assessment of the presenting sleep disturbance to select the optimal available treatment. Cognitivebehavioral therapies (CBTs) are at least as effective as pharmacologic treatment in the short-term and more enduring in their beneficial effects. Cognitive-behavioral treatment for insomnia and imagery rehearsal therapy have been developed to specifically treat insomnia and nightmares and offer promise for more effective relief of these very distressing symptoms. Pharmacotherapy continues to be an important treatment choice for PTSD sleep disturbances as an adjunct to CBT, when CBT is ineffective or not available, or when the patient declines CBT. Great need exists for more investigation into the effectiveness of specific pharmacologic agents for PTSD sleep disturbances and the dissemination of the findings to prescribers. The studies of prazosin and the findings of its effectiveness for PTSD sleep disturbance are examples of studies of pharmacologic agents needed in this area. Despite the progress made in developing more specific treatments for sleep disturbances in PTSD, insomnia and nightmares may not fully resolve.

show abstract

“…The more recent, and also more successful, studies (Brady et al, 2000;Connor et al, 1999;Davidson et al, 2001b;Marshall et al, 2001;Martenyi et al, 2002b;Tucker et al, 2001;van der Kolk et al, 1994) have focused on more general trauma samples that included both men and women with predominately noncombat traumas and have utilized serotonin reuptake inhibitors. Below we describe the major treatments for chronic PTSD that have received empirical support.…”

Section: Interventions For Individuals With Chronic Ptsdmentioning

confidence: 99%

“…Since 1994, three SSRI medications have been shown to be more effective than placebo in the treatment of PTSD: fluoxetine (Connor et al, 1999;Martenyi et al, 2002b;van der Kolk et al, 1994), sertraline (Brady et al, 2000;Davidson et al, 2001b), and paroxetine (Marshall et al, 2001;Tucker et al, 2001). The latter two medications have received the FDA indication for treatment of PTSD.…”

Section: Medicationmentioning

confidence: 99%

Social, Psychological, and Psychiatric Interventions Following Terrorist Attacks: Recommendations for Practice and Research

Foa

Cahill

Boscarino

et al. 2005

Neuropsychopharmacol

View full text Add to dashboard Cite

The terrorist attacks of September 11, 2001, and the constant threat of imminent terrorist activity have brought into the forefront the urgent need to prepare for the consequences of such attacks. Such preparation entails utilization of existing knowledge, identification of crucial gaps in our scientific knowledge, and taking steps to acquire this knowledge. At present, there is little empirical knowledge about interventions following terrorism and absolutely no available empirical knowledge about interventions following bioterrorism. Therefore, this paper reviews knowledge about (1) reactions following the September 11 terrorist attacks in New York City and other places, (2) the practical experiences accumulated in recent years in countries (eg, Israel) that have had to cope with the threat of bioterrorism and the reality of terrorism, and (3) interventions for acute and chronic stress reactions following other types of traumatic events (eg, rape, war, accidents). Our review found several treatments efficacious in treating individuals for acute and chronic post-traumatic stress disorder (PTSD) related to other traumatic events that will likely be efficacious in treating PTSD related to terrorist attacks. However, there were significant gaps in our knowledge about how to prepare populations and individuals for the possibility of a terrorist attack and what interventions to apply in the immediate aftermath of such an attack. Accordingly, we conclude the paper with several questions designed to guide future research.

show abstract

Multicenter, Double-blind Comparison of Sertraline and Placebo in the Treatment of Posttraumatic Stress Disorder

Abstract: The results of the current study suggest that sertraline is a safe, well-tolerated, and significantly effective treatment for PTSD.

Cited by 415 publications

References 43 publications

Quality of Care for PTSD and Depression in the Military Health System: Phase I Report

Quality of Care for PTSD and Depression in the Military Health System: Phase I Report

Treatment of sleep disturbances in posttraumatic stress disorder: A review

Social, Psychological, and Psychiatric Interventions Following Terrorist Attacks: Recommendations for Practice and Research

Contact Info

Product

Resources

About